Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Edison Oncology presented two scientific posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.3
The first poster highlighted early results from a Phase 1-2a clinical trial for VAL-413 (Orotecan), an oral formulation of irinotecan, used in patients with recurrent pediatric solid tumors. No dose limiting toxicity was observed, and pharmacokinetic analysis showed oral Orotecan provided plasma levels similar to intravenous irinotecan given orally in the same patients.1
The second poster focused on EO3001, investigating its therapeutic efficacy against clear cell carcinoma of the ovary. EO3001 was shown to selectively kill ARID1A mutant ovarian cancer cells at low nanomolar concentrations and may act by inhibiting mitochondrial proteins essential for oxidative phosphorylation (OXPHOS), leading to energy deprivation and apoptosis in metabolically active tumor cells with ARID1A mutations.1
These posters demonstrate Edison Oncology’s continuing efforts in developing targeted therapies for difficult-to-treat cancer types, using both novel oral chemotherapeutics and mechanisms exploiting specific genetic vulnerabilities of cancer cells.13
Sources:
1. https://www.edisononcology.com/edison-oncology-announces-presentation-of-two-scientific-posters-at-aacr-annual-meeting